The decision to restrict retigabine (Trobalt) was based on reports of adverse effects in long-term studies, including pigmentation of the skin, nails, lips and ocular tissues (including the retina).
Warn patient and perform eye examination before starting
When initiating therapy, healthcare professionals should inform patients of the risk of pigmentation with long-term treatment and perform a comprehensive ophthalmological examination before starting treatment and at least every 6 months thereafter.
Patients currently receiving retigabine should be identified and reviewed at a routine appointment. In addition, they should have an appointment scheduled for an ophthalmic examination.
Further information: GlaxoSmithKline